The U.S. Food and Drug Administration selected the first nine recipients of its Commissioner’s National Priority Voucher (CNPV) pilot, designating investigational products that can receive an accelerated review window of roughly one to two months. The list—announced by Commissioner Marty Makary—includes drugs and candidates spanning gene therapy, rare disease and oncology, and sent shares of affected companies higher as market participants priced a faster path to approval. BioCentury and industry reports show the picks include investigational and already-approved-abroad products; for some sponsors the voucher could compress timelines for regulatory decisions and commercial launches. Disc Medicine, Regeneron and others named on the list now face expedited interactions with the agency, potentially shifting near-term approval sequencing across several therapeutic areas. The pilot highlights a regulatory experiment that prioritizes select “national priority” products; companies and investors are watching for how the program alters FDA resourcing and review sequencing. Stakeholders caution that faster review still depends on data completeness and FDA agreement on post-approval commitments.